MOG and myeloid sarcoma: However, attempts to translate these findings into human disease have yielded controversial results, especially with regard to MOG antibodies as a prognostic biomarker in MS.11,12 The presence of MOG antibodies confirmed in a subset of predominantly paediatric patients with varying symptomatology, collectively referred to as MOG-associated diseases (MOGAD).11–13